Tag: Coronavirus

1. Hospitalized COVID-19 patients receiving high-dose methylprednisolone followed by oral prednisone had improved clinical outcomes compared to patients receiving dexamethasone. Evidence Rating Level: 2 (Good) In June 2020, a preliminary report of a study was published comparing hospitalized COVID-19 patients receiving dexamethasone (DXM) 6 mg daily (for 10 days) to patients who...
1. A similar proportion of patients died within 28 days of randomization in both groups (high-titre convalescent plasma vs. usual care). 2. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days. Evidence Rating Level: 1 (Excellent) Study Rundown: Convalescent plasma is a...
1. In-hospital mortality within 30 days of admission for COVID-19 was 48% (vs. global mortality 31.5%). 2. Increased age, underlying comorbidities and delay in admission were associated with an increased mortality rate among African patients. Evidence Rating Level: 2 (Good) Study Rundown: The COVID-19 pandemic has exposed long-standing inequities in healthcare. Critically...
1. There was a vaccine efficacy of 97.2% against symptomatic COVID-19 infection in individuals at least 7 days after their second vaccine dose. 2. Substantial and consistent declines in COVID-19 incidence corresponded to greater vaccine coverage. Evidence Rating Level: 2 (Good) Study Rundown: Beyond clinical trials, there is growing evidence of the...
1. Vaccinated individuals reported fewer SARS-CoV-2 infections and a lesser proportion of cases were symptomatic compared to the unvaccinated cohort. 2. BNT162b2 mRNA vaccine showed an effectiveness of 70% 21 days after a single dose. Evidence Rating Level: 2 (Good)  Study Rundown: The BNT162b2 mRNA (Pfizer-BioNTech) and ChAdOx1 nCoV-19 adenoviral (Oxford-AstraZeneca) COVID-19 vaccines have been...
1. Participants identifying as South Asian or Black were more likely to test positive for COVID-19 infection, be hospitalized for COVID-related symptoms, and be admitted to the intensive care unit compared with the White population. 2. In the second wave, the relative rates of COVID-related hospitalization, ICU admission, and death...
1. Compared to usual care, fewer patients in the tocilizumab group died within 28 days of randomization. 2. Patients allocated tocilizumab were more likely to be discharged from the hospital within 28 days. Evidence Rating Level: 1 (Excellent) Study Rundown: Hypoxic respiratory failure in patients with COVID-19 is associated with systemic inflammation, alveolar damage,...
1. Vaccinated individuals reported fewer SARS-CoV-2 infections and a lesser proportion of cases were symptomatic compared to the unvaccinated cohort. 2. BNT162b2 mRNA vaccine showed an effectiveness of 70% 21 days after a single dose. Evidence Rating Level: 2 (Good)  Study Rundown: The BNT162b2 mRNA (Pfizer-BioNTech) and ChAdOx1 nCoV-19 adenoviral (Oxford-AstraZeneca) COVID-19...
1. Compared to usual care, fewer patients in the tocilizumab group died within 28 days of randomization. 2. Patients allocated tocilizumab were more likely to be discharged from the hospital within 28 days. Evidence Rating Level: 1 (Excellent) Study Rundown: Hypoxic respiratory failure in patients with COVID-19 is associated with systemic inflammation,...
1. The ChAdOx1 nCov-19 (AstraZeneca) vaccine was not effective for the prevention of mild-to-moderate COVID-19 infection caused by the B.1.351 variant.  2. The ChAdOx1 nCov-19 vaccine was effective against mild-to-moderate non-variant COVID-19 infection after a single injection. Evidence Rating Level: 1 (Excellent)      Study Rundown: With the emergence of COVID-19 variants, there is the...